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Correlation Between Dose and Level of Cyclosporine After Orthotopic Liver 
Transplantation 
D. Kahn. V. Mazzaferro. G. Cervio. R. Venkataramanan. L. Makowka. D.H. Van Thiel. and T.E. Starzl 
I t is generally accepted that. in actual clinical practice. the 
concentration of cyclosporine in blood is the principal 
determinant of the dosage to be prescribed for a given 
patient. However. many physicians. in describing immuno-
suppression policies. still refer to the dose of cyclosporine 
prescribed after transplantation. The present analysis was 
undertaken to determine the degree of correlation between 
the dose and level of cyclosporine in s' able liver transplant 
reci pien ts. 
PATIENTS AND METHODS 
The records of all adult patients who u,derwent orthotopic liver 
transplantation at the Presbyterian-univ sity Hospital. Pittsburgh. 
between January and October 1987 ... ere evaluated. 
Immunosuppression Protocol 
The techniques for orthotopic liver transolantation and immunosup-
pressive protocols utilized in these cases have been described in detail 
prevlouslyU In particular. all patients ... ere treated with a .;;ombina-
tlon of cyclosporine and steroids, C~c!osporine (17,5 mg/kg) was 
administered orally preoperatively, During the operation ~edrol I g 
and cyclosporine (2 mgjkg) were given Intravenously at the time of 
revascularization of the graft. Postoperatively. the patients received 
\ledrol 200 mg. which was reduced by 40 mg daily until a 
maintenance dose of 20 mg dally ... as achieved. and cyclosporine 6 
mg/kg intravenously in 3 divided doses, Oral cyclosporine (20 
mg/kg) was Introduced as soon as the patients had stabilized after 
the transplant procedure and resumed an oral diet. The dose of 
cyciospoTine was adjusted to maintain a 12·hour cvclosporine whole 
blood trough bel of approximately 1000 ng/mL 
Rejection epllodes. In the presence of adequate cyclo,porlne 
levels, ... ere treated with a solumedrol bolus A re·cycle of the 
\ledrol ... as used In the patients who failed to respond to the sterOid 
bolus, SterOid reSistant rejection episodes ... ere treated with the 
monoclonal antlMy OKT), 
C~closponne levels were determined on whole blood utilizing a 
radioimmunoassay kit obtained fl <)m Sandoz, 
The" hole blood cydosponne b'eJ achieved and the dose of 
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Fig 1. Do .. of cyclo.porlne (mg/kg/day) uled by the liver 
tran.plant recipient •• tudled. 
cyclosporine used for each patient at the time of the first outpatient 
visit were recorded. This lime-point for analysis was chosen because 
patients are discharged from hospital only if graft function and 
whole blood cyclosporine levels are stable. Typically patients are 
discharged three to eight weeks after transplantation. 
RESULTS 
Thirty-one male and 44 female consecutive adult liver trans-
plant recipients who survived for greater than 3 months with 
stable allograft function were included in the study. The 
mean age of the patients was 43.36 ± 1,33 years 
(mean ± SEM) and the ages ranged from 21 to 70 years. 
The doses of cyclosporine used in these patients. as shown 
in Fig I. ranged from 6 to 57 mg/kg/day and the median 
dose was IS mg/kg/day. Thirteen transplant recipients 
(17.3%) received doses less than 12 mg/kg/day while II 
patients (14.7%) required doses greater than 22 mg/kg/ 
day. 
The concentrations of cyclosporine in the blood in these 
stable allograft recipients are shown in Fig 2. The median 
cyclosporine level was 1025 ng/mL with a range of 180 to 
1925 ng/mL The cyclosporine level in one patient was only 
180 ng/mL However. despite this inadequate cyclosporine 
level. this patient had normal bilirubin and transaminase 
levels, The remaining 74 liver recipients had cyclosporine 
levels greater than 500 ng/mL Cyclosporine levels greater 
than 1600 ng/mL were found in selien patients (9,37.), 
The ideal cyclosponne leli'el in liver transplant reCipients 
with normal hepatic function and without any eVidence of 
cyclosporine toxicity. in ou r Inst itut ion. shou Id be bet II. een 
700 and 1300 nglmL In this study 52 patients (6937r) had 
cyclosponne levels Within thiS range (Fig 3), The median 
dose of cyclosporine required to malnt~lfn ideal levels was 13 
mg/kg/da) with a range of 6 to 57 mg/kg/day, This dose of 
cyclosponne required to maintain Ideal levels was less than 
10 mg/kg/da) in nine patients ( 17 ,3,}) a nd was greater than 
23 mg/kg/day in II patients. 
DISCUSSION 
Descriptions of the immunosuppression protocols used after 
organ transplantallon typically refer to the dose of cyc1ospo-
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Fig 2. Concentration of cyclo,porine in whole blood (ngl 
mL) In liver allograft reclplentl. 
rine (on a per weight basis) given to patients. In actual 
clinical practice. however, the amount of cyclosporine given 
to patients is determined principally by the level of the drug 
in the blood. This analysis of the amount of cyclosporine 
administered to and the concentration of cyclosporine 
achieved in whole blood in 75 liver allograft recipients 
revealed that the majority of patients had levels of cyclospo-
rine within the standard or universally accepted "therapeu-
tic" range. A few patients with stable graft function had 
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Fig 3. Do .. of cyclolporlne (mg/kg/day) required to 
achieve a cyclolporlne level 0' 7()()'1300 ng/mL In live, 
transplant reclplentl. 
levels which were outside the therapeutic range. The dose of 
cyclosporine rC{juired to maintain these levels varied widely 
in these patients. 
Furthermore, this study demonstrated that the trough 
concentration of cyclosporine achieved in blood did not 
correlate with the dose of cyclosporine administered to stable 
transplant recipients. This study emphasizes the fact that 
immunosuppression protocols must include measurements of 
the level of cyclosporine achieved in blood and not simply the 
dose of the drug administered. 
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